In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Consumer Platform Technologies

PhytoBioSystems

Executive Summary

A University of Massachusetts spin-off, PhytoBioSystems will develop plant extract products that will boost human disease resistance as well as provide a means of natural food preservation.

You may also be interested in...



Aurobindo Upbeat On Outlook, Transfers Biologics Biz

After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.    

Some Annex XVI Products Likely To Be Delayed, Latest Commission Updated Rolling Plan Suggests

The European Commission has updated its rolling plan. It now looks as if current member state rules for non-medical products could persist beyond the 26 May 2021 deadline.

GSK Tapping Into Naturals Trend With UK Piri Extension

GSK launches a 100% natural saline spray in the UK to compliment its Piri hayfever brand portfolio.

Table

View full table

Topics

Related Companies

Related Deals

Tags:
BioPharmaceutical Consumer Platform Technologies
UsernamePublicRestriction

Register

PL008388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By